Evidence map›Paper›PMID 33956802›Full record

Trial reportPLoS medicine2021

Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda.

Adithya Cattamanchi, Rebecca Crowder, Alex Kityamuwesi, Noah Kiwanuka, Maureen Lamunu, Catherine Namale, Lynn Kunihira Tinka, Agnes Sanyu Nakate, Joseph Ggita, Patricia Turimumahoro and 9 more

Open access · goldAbstract readRandomized Controlled TrialPragmatic Clinical Trial
In one paragraph

Trial report in PLoS medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 6 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 6 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Adithya CattamanchiCenter for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.ORCID 0000-0002-6553-2601
Rebecca CrowderCenter for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.ORCID 0000-0001-6374-3088
Alex KityamuwesiUganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.ORCID 0000-0002-1689-5748
Noah KiwanukaDepartment of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.ORCID 0000-0003-2471-9290
Maureen LamunuUganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.ORCID 0000-0001-9129-0493
Catherine NamaleUganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.ORCID 0000-0001-9830-2266
Lynn Kunihira TinkaUganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.
Agnes Sanyu NakateUganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.
Joseph GgitaUganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.ORCID 0000-0001-9282-563X
Patricia TurimumahoroUganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.ORCID 0000-0003-1910-8559
Diana BabiryeUganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.ORCID 0000-0002-8525-0927
Denis OyukuUganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.
Christopher BergerCenter for Tuberculosis and Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.ORCID 0000-0002-0034-7544
Austin TuckerDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID 0000-0002-3397-2565
Devika PatelThe Better Lab, Department of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.ORCID 0000-0002-1479-3588
Amanda SammannThe Better Lab, Department of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.ORCID 0000-0002-8044-7165
Stavia TuryahabweNational Tuberculosis and Leprosy Program, Uganda Ministry of Health, Kampala, Uganda.ORCID 0000-0002-9537-4448
David DowdyUganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.ORCID 0000-0003-0481-7475
Achilles KatambaUganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.ORCID 0000-0002-2347-4183
San Francisco General Hospital · USJohns Hopkins University · USMakerere University · UGMinistry of Health · UG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdherence to and completion of tuberculosis (TB) treatment remain problematic in many high-burden countries. 99DOTS is a low-cost digital adherence technology that could increase TB treatment completion. METHODS AND

findingsWe conducted a pragmatic stepped-wedge cluster-randomized trial including all adults treated for drug-susceptible pulmonary TB at 18 health facilities across Uganda over 8 months (1 December 2018-31 July 2019). Facilities were randomized to switch from routine (control period) to 99DOTS-based (intervention period) TB treatment supervision in consecutive months. Patients were allocated to the control or intervention period based on which facility they attended and their treatment start date. Health facility staff and patients were not blinded to the intervention. The primary outcome was TB treatment completion. Due to the pragmatic nature of the trial, the primary analysis was done according to intention-to-treat (ITT) and per protocol (PP) principles. This trial is registered with the Pan African Clinical Trials Registry (PACTR201808609844917). Of 1,913 eligible patients at the 18 health facilities (1,022 and 891 during the control and intervention periods, respectively), 38.0% were women, mean (SD) age was 39.4 (14.4) years, 46.8% were HIV-infected, and most (91.4%) had newly diagnosed TB. In total, 463 (52.0%) patients were enrolled on 99DOTS during the intervention period. In the ITT analysis, the odds of treatment success were similar in the intervention and control periods (adjusted odds ratio [aOR] 1.04, 95% CI 0.68-1.58, p = 0.87). The odds of treatment success did not increase in the intervention period for either men (aOR 1.24, 95% CI 0.73-2.10) or women (aOR 0.67, 95% CI 0.35-1.29), or for either patients with HIV infection (aOR 1.51, 95% CI 0.81-2.85) or without HIV infection (aOR 0.78, 95% CI 0.46-1.32). In the PP analysis, the 99DOTS-based intervention increased the odds of treatment success (aOR 2.89, 95% CI 1.57-5.33, p = 0.001). The odds of completing the intensive phase of treatment and the odds of not being lost to follow-up were similarly improved in PP but not ITT analyses. Study limitations include the likelihood of selection bias in the PP analysis, inability to verify medication dosing in either arm, and incomplete implementation of some components of the intervention.

conclusions99DOTS-based treatment supervision did not improve treatment outcomes in the overall study population. However, similar treatment outcomes were achieved during the control and intervention periods, and those patients enrolled on 99DOTS achieved high treatment completion. 99DOTS-based treatment supervision could be a viable alternative to directly observed therapy for a substantial proportion of patients with TB.

trial registrationPan-African Clinical Trials Registry (PACTR201808609844917).

Indexed as

Drug MonitoringAdultAntitubercular AgentsCluster AnalysisFemaleHumansMaleMiddle AgedTechnologyTuberculosis, PulmonaryUgandaYoung AdultAntitubercular Agents

Identifiers

PMID33956802
PMCPMC8136841
OpenAlexW3157487954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.